Nanlin Hu1, Anjie Zhu1,2, Yiran Si1, Jian Yue3, Xue Wang3, Jiayu Wang1, Fei Ma1, Binghe Xu1, Peng Yuan3. 1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Department of Breast Oncology, Peking University Cancer Hospital/Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China. 3. Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
INTRODUCTION: We performed this clinical trial to evaluate the efficacy and safety of apatinib and oral etoposide in patients with HER2-negative locally advanced or metastatic breast cancer (MBC). METHODS: Patients with HER2-negative MBC previously treated with anthracycline and taxanes and failed ≥1 prior chemotherapy regimens were recruited. The starting dose of apatinib was 500 and 425 mg in patients with ECOG scores of 0-1 and 2, respectively. The etoposide capsules were given at 50 mg/m2 on days 1 to 10 for 21 days. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. RESULTS: Thirty-one eligible patients were enrolled. The median follow-up time was 11 months. The median PFS for all patients was 6.9 months [95% confidence interval (CI) 6.0-7.9], and 6.9 months (95% CI 5.3-8.6) and 6.6 months (95% CI 1.4-11.7) for patients with apatinib 425 and 500mg once daily, respectively. The ORR was 35.5% (11/31). The DCR was 87.1% (27/31). The median OS was 20.4 months (95% CI 11.4-29.3). The median PFS of patients who had hypertension and proteinuria was longer than that for those without hypertension and proteinuria. The most common grade 3/4 treatment-related AEs were hypertension (12/31, 38.7%), fatigue (3/31, 9.7%), thrombocytopenia (3/31, 9.7%). CONCLUSION: Apatinib combined with etoposide capsules is effective and tolerable in heavily pretreated, metastatic HER2-negative breast cancer patients. A lower apatinib dose provide equivalent efficacy and reduced toxicity. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT03535961.
INTRODUCTION: We performed this clinical trial to evaluate the efficacy and safety of apatinib and oral etoposide in patients with HER2-negative locally advanced or metastatic breast cancer (MBC). METHODS: Patients with HER2-negative MBC previously treated with anthracycline and taxanes and failed ≥1 prior chemotherapy regimens were recruited. The starting dose of apatinib was 500 and 425 mg in patients with ECOG scores of 0-1 and 2, respectively. The etoposide capsules were given at 50 mg/m2 on days 1 to 10 for 21 days. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. RESULTS: Thirty-one eligible patients were enrolled. The median follow-up time was 11 months. The median PFS for all patients was 6.9 months [95% confidence interval (CI) 6.0-7.9], and 6.9 months (95% CI 5.3-8.6) and 6.6 months (95% CI 1.4-11.7) for patients with apatinib 425 and 500mg once daily, respectively. The ORR was 35.5% (11/31). The DCR was 87.1% (27/31). The median OS was 20.4 months (95% CI 11.4-29.3). The median PFS of patients who had hypertension and proteinuria was longer than that for those without hypertension and proteinuria. The most common grade 3/4 treatment-related AEs were hypertension (12/31, 38.7%), fatigue (3/31, 9.7%), thrombocytopenia (3/31, 9.7%). CONCLUSION: Apatinib combined with etoposide capsules is effective and tolerable in heavily pretreated, metastatic HER2-negative breast cancer patients. A lower apatinib dose provide equivalent efficacy and reduced toxicity. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT03535961.
Authors: John P Crown; Véronique Diéras; Elzbieta Staroslawska; Denise A Yardley; Thomas Bachelot; Neville Davidson; Hans Wildiers; Peter A Fasching; Olivier Capitain; Manuel Ramos; Richard Greil; Francesco Cognetti; George Fountzilas; Maria Blasinska-Morawiec; Cornelia Liedtke; Rolf Kreienberg; Wilson H Miller; Vanessa Tassell; Xin Huang; Jolanda Paolini; Kenneth A Kern; Gilles Romieu Journal: J Clin Oncol Date: 2013-07-15 Impact factor: 44.544
Authors: Kamila Buzun; Agnieszka Gornowicz; Roman Lesyk; Anna Kryshchyshyn-Dylevych; Andrzej Gzella; Robert Czarnomysy; Gniewomir Latacz; Agnieszka Olejarz-Maciej; Jadwiga Handzlik; Krzysztof Bielawski; Anna Bielawska Journal: Int J Mol Sci Date: 2022-04-07 Impact factor: 6.208